“…Prostate cancer (PCa) is the most commonly diagnosed cancer and second leading cause of cancerrelated deaths among males worldwide, with an estimated annual incidence of 191,930 in the United States in 2020, and estimated deaths of 33,330 per year (Siegel et al, 2020). PCa usually contains multifocal lesions (with varying genetic alterations) and is heterogenous at the molecular, cellular and architectural levels (Zhang et al, 2016), which makes obtaining a homogenous material for molecular analysis difficult (Abate- Shen and Shen, 2000;Bahmad et al, 2020b;Daouk et al, 2020). The heterogeneity of this tumor also renders choosing the best therapy for each patient (castration therapy, surgery, radiotherapy, or chemotherapy) very challenging (Karantanos et al, 2013;Zhang et al, 2016).…”